PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsSunitinib
Sutent(sunitinib)
Sunitinib, Sutent (sunitinib) is a small molecule pharmaceutical. Sunitinib was first approved as Sutent on 2006-01-26. It is used to treat gastrointestinal stromal tumors, neuroendocrine tumors, pancreatic neoplasms, and renal cell carcinoma in the USA. It has been approved in Europe to treat gastrointestinal stromal tumors, neuroendocrine tumors, and renal cell carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 3, mast/stem cell growth factor receptor Kit, and platelet-derived growth factor receptor beta. In addition, it is known to target fibroblast growth factor receptor 1, proto-oncogene tyrosine-protein kinase receptor Ret, receptor-type tyrosine-protein kinase FLT3, and vascular endothelial growth factor receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
urogenital diseasesD000091642
endocrine system diseasesD004700
Trade Name
FDA
EMA
Sunitinib, Sutent
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sunitinib malate
Tradename
Company
Number
Date
Products
SUTENTCP Pharmaceuticals International CVN-021938 RX2006-01-26
4 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
sunitinib malateANDA2026-01-16
sutentNew Drug Application2026-02-20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EX: Other protein kinase inhibitors in atc
— L01EX01: Sunitinib
HCPCS
No data
Clinical
Clinical Trials
602 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal cell carcinomaD002292EFO_0000376—319832770227
CarcinomaD002277—C80.0157715538144
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A17341322182
NeoplasmsD009369—C803328311778
Breast neoplasmsD001943EFO_0003869C50122141335
Non-small-cell lung carcinomaD002289——41321120
Neuroendocrine tumorsD018358EFO_1001901D3A.83911620
Gastrointestinal neoplasmsD005770—C26.92311511
Islet cell adenomaD007516EFO_0007331D13.72321210
Thyroid neoplasmsD013964EFO_0003841——6—129
Show 3 more
Indications Phases 3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary bladder neoplasmsD001749—C67113———13
MelanomaD008545——311———12
SarcomaD012509——49———11
Transitional cell carcinomaD002295———10———10
Stomach neoplasmsD013274EFO_0003897C1645——110
AdenocarcinomaD000230———8———8
LeukemiaD007938—C9524——17
Myeloid leukemia acuteD015470—C92.043——17
Multiple myelomaD009101—C90.025———7
LymphomaD008223—C85.924——17
Show 134 more
Indications Phases 1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10————55
CardiotoxicityD066126EFO_1001482—————44
FatigueD005221—R53.83————44
Torsades de pointesD016171EFO_0005307I47.21————22
Heart failureD006333EFO_0003144I50————22
Acute diseaseD000208——————11
Long qt syndromeD008133HP_0001657I45.81————11
DeliriumD003693—R41.0————11
Renal insufficiencyD051437—N19————11
Insulin resistanceD007333EFO_0002614E88.819————11
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSunitinib
INNsunitinib
Description
Sunitinib is a member of pyrroles and a monocarboxylic acid amide. It has a role as an angiogenesis inhibitor, an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a vascular endothelial growth factor receptor antagonist, an immunomodulator and a neuroprotective agent. It is functionally related to a 3-methyleneoxindole.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C
Identifiers
PDB—
CAS-ID557795-19-4
RxCUI—
ChEMBL IDCHEMBL535
ChEBI ID38940
PubChem CID5329102
DrugBankDB01268
UNII IDV99T50803M (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
FGFR1
FGFR1
Organism
Homo sapiens
Gene name
FGFR1
Gene synonyms
BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR
NCBI Gene ID
Protein name
fibroblast growth factor receptor 1
Protein synonyms
Basic fibroblast growth factor receptor 1, bFGF-R-1, BFGFR, CD331, FGFR1/PLAG1 fusion, FLT-2, FMS-like tyrosine kinase 2, fms-related tyrosine kinase 2, heparin-binding growth factor receptor, hydroxyaryl-protein kinase, N-sam, Proto-oncogene c-Fgr
Uniprot ID
Mouse ortholog
Fgfr1 (14182)
fibroblast growth factor receptor 1 (P16092)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Sutent – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
Black-box warning for: Sunitinib malate, Sutent
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
50,273 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use